IKT Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain...

Stats
Dzisiejszy wolumen	69 360.00
Średni wolumen	95 055.00
Kapitalizacja rynkowa	8.68M
EPS	$0 ( 2024-03-29 )
Następna data zysków	( $-0.790 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.380
ATR14	$0.00700 (0.53%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Werner Milton H.	Buy	45 000	Stock Option (right to buy)
2024-04-01	Lees-rolfe Garth	Buy	90 000	Stock Option (right to buy)
2024-04-01	Lees-rolfe Garth	Sell	5 834	Stock Option (right to buy)
2023-06-30	Berman Dennis N	Buy	6 667	Stock Option (right to buy)
2023-06-30	Dion Gisele	Buy	6 667	Stock Option (right to buy)

INSIDER POWER
96.49
Last 62 transactions
Buy: 1 923 769 \| Sell: 2 120 717

Wolumen Korelacja

Długi: -0.02 (neutral)

Krótki: -0.79 (moderate negative)

Signal:(56.802) Neutral

Inhibikase Therapeutics, Korelacja

10 Najbardziej pozytywne korelacje
ECOR	0.835
CPLP	0.833
PROV	0.828
SVOK	0.82
CLST	0.816
BHFAO	0.815
CFBK	0.815
MREO	0.811
OCCIO	0.809
HMST	0.806

10 Najbardziej negatywne korelacje
OSMT	-0.843
VISL	-0.821
IQ	-0.82

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Inhibikase Therapeutics, Korelacja - Waluta/Towar

-0.48
( neutral )

-0.40
( neutral )

0.00
( neutral )

-0.44
( neutral )

-0.50
( weak negative )

0.33
( neutral )

Inhibikase Therapeutics, Finanse

Annual	2023
Przychody:	$260 500
Zysk brutto:	$83 102.00 (31.90 %)
EPS:	$-3.57

FY	2023
Przychody:	$260 500
Zysk brutto:	$83 102.00 (31.90 %)
EPS:	$-3.57

FY	2022
Przychody:	$123 440
Zysk brutto:	$116 717 (94.55 %)
EPS:	$-4.26

FY	2021
Przychody:	$3.10M
Zysk brutto:	$3.10M (100.00 %)
EPS:	$-0.810

Financial Reports:

No articles found.

Inhibikase Therapeutics,

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.